Edgar Filing: Epizyme, Inc. - Form 4

Epizyme, In Form 4 June 18, 201										
FORM	14							OMB A	PPROVAL	
	UNITED ST	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235-0287	
Check th if no long	aar.							Expires:	January 31, 2005	
subject to Section 1 Form 4 c	or STATEVIE N 16. 07	STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIES						Estimated average burden hours per response 0		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type]	Responses)									
			2. Issuer Name and Ticker or Trading Symbol Epizyme, Inc. [EPZM]				5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (Middl		_	_			(Chec	k all applicable	;)	
(Mon			3. Date of Earliest Transaction (Month/Day/Year) 06/16/2014				Director 10% Owner X Officer (give title Other (specify below) below) Chief Medical Officer			
CAMBRID	(Street) GE, MA 02139		endment, Da onth/Day/Year	-	1		6. Individual or Jo Applicable Line) _X_ Form filed by O Form filed by M	One Reporting Pe	rson	
(City)	(State) (Zip)						Person			
						-	uired, Disposed of		-	
1.Title of Security (Instr. 3)	(Month/Day/Year) Ex an	nth/Day/Year) Execution Date, if any			3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, par value \$0.0001 per share	06/16/2014		M <u>(1)</u>		A		2,000	D		
Common Stock, par value \$0.0001 per share	06/16/2014		S <u>(1)</u>	2,000	D	\$ 26.42	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number omf Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. l De Seo (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 2.19	06/16/2014		M <u>(1)</u>	2,000	(2)	06/06/2022	Common Stock	2,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Hedrick Eric C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139			Chief Medical Officer				
Signatures							
/s/ Stephen Garbacz, attorney-in-fact	0	6/18/2014					

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- (2) This option was granted on June 7, 2012 with respect to 300,000 shares of Common Stock, with 25% vesting on May 8, 2013 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.